Coherus Oncology (CHRS) will distribute a special dividend of contingent value rights to stockholders, entitling them to the net proceeds from the sale of remaining legacy biosimilar assets. This restructuring measure underscores the company’s strategic pivot to focus exclusively on innovative immuno-oncology therapies.